<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04562402</url>
  </required_header>
  <id_info>
    <org_study_id>1956-P</org_study_id>
    <nct_id>NCT04562402</nct_id>
  </id_info>
  <brief_title>Phaco-ECP vs Phaco Alone in Primary Angle Closure</brief_title>
  <acronym>PHEPHA</acronym>
  <official_title>Phacoemulsification With Endoscopic Cyclophotocoagulation vs Phacoemulsification Alone in Primary Angle Closure (PHEPHA): A Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>King Khaled Eye Specialist Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>King Khaled Eye Specialist Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparison between phacoemulsification with endoscopic cyclophotocoagulation versus&#xD;
      phacoemulsification alone in patients with either primary angle closure or primary angle&#xD;
      closure glaucoma presenting with cataract or a clear lens.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of our current randomized clinical trial is to compare phacoemulsification with&#xD;
      endoscopic cyclophotocoagulation (PHE) versus phacoemulsification alone (PHA) in patients&#xD;
      with either primary angle closure (PAC) or primary angle closure glaucoma (PACG) presenting&#xD;
      with cataract or a clear lens.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 16, 2020</start_date>
  <completion_date type="Anticipated">February 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 15, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intraocular Pressure (IOP)</measure>
    <time_frame>12 months</time_frame>
    <description>Change in IOP between baseline (pre-intervention) and the last follow-up visit</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of glaucoma medications</measure>
    <time_frame>12 months</time_frame>
    <description>Change in the number of glaucoma medications between baseline (pre-intervention) and the last follow-up visit</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">104</enrollment>
  <condition>Glaucoma, Angle-Closure</condition>
  <arm_group>
    <arm_group_label>Phacoemulsification with endoscopic cyclophotocoagulation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cataract extraction via phacoemulsification along with endoscopic cyclophotocoagulation of the ciliary body.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phacoemulsification alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cataract extraction via phacoemulsification.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Phacoemulsification</intervention_name>
    <description>cataract surgery via phacoemulsification</description>
    <arm_group_label>Phacoemulsification alone</arm_group_label>
    <arm_group_label>Phacoemulsification with endoscopic cyclophotocoagulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Endoscopic cyclophotocoagulation</intervention_name>
    <description>Endoscopic ablation of the ciliary body</description>
    <arm_group_label>Phacoemulsification with endoscopic cyclophotocoagulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age is above 40 years old.&#xD;
&#xD;
          2. A diagnosis of either PAC or PACG. PAC will be defined as the presence of&#xD;
             irido-trabecular contact on gonioscopy, either appositional or in the presence of&#xD;
             peripheral anterior synechiae (PAS), without indentation (or prior documentation&#xD;
             before a LPI has been performed) without any evidence of glaucomatous optic&#xD;
             neuropathy. PACG will be defined as PAC along with an evidence of glaucomatous optic&#xD;
             neuropathy. An optic neuropathy secondary to glaucoma will be defined as evidence of&#xD;
             structural and functional damage suggestive of glaucoma as demonstrated by clinical&#xD;
             examination, optical coherence tomography, and visual field testing.&#xD;
&#xD;
          3. IOP measurement that is more than 21 mmHg (not exceeding 35 mmHg) without the use of&#xD;
             glaucoma medications or less than 21 mmHg with medications.&#xD;
&#xD;
          4. Patient is able to give an informed consent and tolerate a period of medication&#xD;
             washout.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous intraocular surgery (including CPC). Glaucoma laser procedures are allowed&#xD;
             (e.g. LPI, iridoplasty, and laser trabeculoplasty).&#xD;
&#xD;
          2. Previous ocular trauma.&#xD;
&#xD;
          3. A central corneal thickness that does not lie between 500 and 600 microns.&#xD;
&#xD;
          4. A diagnosis of nanophthalmos (defined as an axial length that is less than 20 mm).&#xD;
&#xD;
          5. Presence of pseudoexfoliation.&#xD;
&#xD;
          6. Presence of secondary causes of angle closure such as neovascular glaucoma and uveitic&#xD;
             glaucoma.&#xD;
&#xD;
          7. Presence of diabetic retinopathy (active PDR or active DME) or agerelated macular&#xD;
             degeneration. PHEPHA Protocol Version 2 September 3, 2020&#xD;
&#xD;
          8. Advanced glaucoma as defined by the Glaucoma Severity Staging System12 (mean deviation&#xD;
             worse than -12.01 dB and at least one of the following: 1. On pattern deviation plot,&#xD;
             greater than or equal to 50% but fewer than 75% of points depressed below the 5% level&#xD;
             and greater than or equal to 25% but fewer than 50% of points depressed below 1% level&#xD;
             2. Any point within central 5 degrees with sensitivity &lt; 0db 3. Both hemifields&#xD;
             containing a point(s) with sensitivity &lt; 15 dB within 5 degrees of fixation).&#xD;
&#xD;
          9. Any ocular or systemic condition that is presumed to prevent reliable clinical&#xD;
             examination and/or visual field testing.&#xD;
&#xD;
         10. Pregnancy.&#xD;
&#xD;
         11. Inability to attend postoperative follow ups for a period of 12 months after surgery.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adi Al Owaifeer, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>King Khaled Eye Specialist Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ibrahim Alobaida, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>King Khaled Eye Specialist Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Muneera AlFutais</last_name>
    <phone>+966114849700</phone>
    <phone_ext>1374</phone_ext>
    <email>mfutais@kkesh.med.sa</email>
  </overall_contact>
  <location>
    <facility>
      <name>King Khaled Eye Specialist Hospital</name>
      <address>
        <city>Riyadh</city>
        <zip>11462</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Muneera AlFutais</last_name>
      <phone>+966114849700</phone>
      <phone_ext>1374</phone_ext>
      <email>mfutais@kkesh.med.sa</email>
    </contact>
    <investigator>
      <last_name>Adi Al Owaifeer, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ibrahim Alobaida, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Saudi Arabia</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 18, 2020</study_first_submitted>
  <study_first_submitted_qc>September 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 24, 2020</study_first_posted>
  <last_update_submitted>September 18, 2020</last_update_submitted>
  <last_update_submitted_qc>September 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>King Khaled Eye Specialist Hospital</investigator_affiliation>
    <investigator_full_name>Adi Al Owaifeer, MBBS</investigator_full_name>
    <investigator_title>Consultant</investigator_title>
  </responsible_party>
  <keyword>Glaucoma</keyword>
  <keyword>Endoscopic cyclophotocoagulation</keyword>
  <keyword>Laser</keyword>
  <keyword>Intraocular pressure</keyword>
  <keyword>Phacoemulsification</keyword>
  <keyword>Primary angle closure glaucoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Angle-Closure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

